A recent attempt to develop a biomarker-driven treatment for SCLC was that of rovalpitumab tesirine, an antibody drug conjugate targeting the NOTCH ligand delta-like 3 protein (DLL-3). This evidence concerns the gene DLL3 and small cell lung carcinoma.